Understanding how type III collagen affects cancer cell dormancy and metastasis
Defining the role of type III collagen and the collagen-binding receptor DDR1 in metastatic dormancy
This study is looking at how a specific protein and its receptor help cancer cells stay inactive for a long time after treatment, which could help us find new ways to stop cancer from coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10893967 on NIH RePORTER |
What this research studies
This research investigates the role of type III collagen and its receptor DDR1 in the process of cancer cell dormancy, which can occur after initial treatment. The study aims to understand how cancer cells can remain inactive for years before potentially reactivating and spreading to other organs. By examining the interactions between these dormant cells and their surrounding extracellular matrix, the research seeks to uncover the mechanisms that allow these cells to survive and remain dormant. This could lead to new insights into preventing cancer recurrence.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who have completed treatment and are in remission but may be at risk for metastasis.
Not a fit: Patients with non-cancerous conditions or those who are currently undergoing active cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing cancer recurrence by targeting the mechanisms that allow dormant cancer cells to survive.
How similar studies have performed: Previous research has shown promising results in understanding tumor dormancy and its mechanisms, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Bravo-Cordero, Jose Javier — Icahn School of Medicine at Mount Sinai
- Study coordinator: Bravo-Cordero, Jose Javier
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.